ArticleCurrent microbiology2026
Phellinus pini Polysaccharides Regulate Gut Microbiota-Host Metabolism to Attenuate Influenza-Driven Lung Injury.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Phellinus pini is a large fungus with significant medicinal value. Building on the previously discovered inhibitory activity of Phellinus pini polysaccharides (PPP) against influenza viruses, this study established an influenza A mouse model through the intranasal instillation of an H1N1/PR8 virus solution. Using a combination of metabolomics and gut microbiota analysis techniques, the study further elucidated a novel mechanism by which PPP regulates influenza-induced lung damage via the "gut-lung axis". Results showed PPP reversed lung lesions, reduced the lung index and viral load in lung tissue, and exerted anti-inflammatory effects by downregulating inflammatory cytokine expression, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). Additionally, 49 potential biomarkers were identified in fecal samples collected from mice infected with influenza A. After low-dose PPP administration, 16 of these biomarkers returned to normal levels. Further pathway analysis revealed that PPP primarily exerts its antiviral effects by influencing pyrimidine metabolism, steroid hormone biosynthesis, tyrosine metabolism. Gut microbiota analysis revealed that PPP improves the gut microbiota environment by significantly increasing the abundance of beneficial bacteria, such as Alistipes, which is closely related to fructose and mannose metabolism and β-lactam resistance pathways. Spearman's correlation analysis revealed that the 16 PPP-regulated biomarkers were correlated with Alistipes and pharmacological parameters. These integrated results suggest a potential mechanism by which PPP alleviates influenza-driven lung injury through the modulation of the gut microbiota-host metabolism axis. This study provides correlative evidence supporting the involvement of the gut-lung axis in PPP's protective effects, offering theoretical insights for future antiviral research.
Indexed as
Identifiers
41957294What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.